武清区龙济医院泌尿医院咋样天津省天津武清区龙济医院是正规的吗,龙济医院详细地址,天津武清龙济男泌尿科,武清区龙济男科点评,天津市武清区龙济医院公交车,环球置地广场与天津市龙济医院男科医院近吗,武清区龙济男科医院平价

The cost of the Justice Department's ongoing investigation into Russia's interference in the 2016 election is now roughly million, according to a new report filed Friday by the special counsel's office.Friday's accounting provided the latest figures covering only the period for April 2018 through September 2018, with special counsel Robert Mueller listing direct expenditures of nearly .6 million.Another roughly .9 million was reported as costs for the work of other Justice and FBI officials who have assisted the investigation but are not under Mueller's direct control. According to the report, those investigation costs would have been incurred "irrespective of the existence of the (special counsel's office)."The department previously reported .7 million in direct and indirect costs from May through September 2017, and  million from October 2017 through March 2018 -- bringing the total from all three reports over the life of the investigation to just over million. Of that amount, only .3 million is the special counsel's direct expenditures.Since taking control of the Russia probe in May 2017, Mueller has advanced on multiple fronts to investigate any links between the Russian government and the Trump campaign, along with other crimes arising from the investigation.To date, the investigation has yielded charges against 36 people or entities. Seven people have pleaded guilty to various charges, including President Donald Trump's first national security adviser, Michael Flynn, former campaign chairman Paul Manafort, former deputy campaign chairman Rick Gates and former campaign foreign policy adviser George Papadopoulos.Meanwhile, Trump and his allies have relentlessly attacked Mueller and the probe as a waste of money.Trump took aim at the cost of the investigation last month, offering a grab-bag of different numbers Mueller had allegedly spent, untethered to the facts.On November 27, 2018 he tweeted: "now ,000,000 Witch Hunt continues and they've got nothing but ruined lives."Then 48 hours later, he tweeted criticizing the "witch hunt" for "wasting more than ,000,000." 2182

The Food and Drug Administration released updated safety standards Tuesday for makers of COVID-19 vaccines despite efforts by the White House to block them, clearing the way for requirements that are widely expected to prevent the introduction of a vaccine before Election Day.In the new guidelines posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out any major side effects before seeking emergency approval. That standard had been a sticking point between the FDA and White House officials, who said it could unreasonably delay the availability of COVID-19 vaccines.President Donald Trump has repeatedly insisted a vaccine could be authorized before Nov. 3, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House.Former FDA officials have warned that public perception that a vaccine was being rushed out for political reasons could derail efforts to vaccinate millions of Americans.A senior administration official confirmed Monday that the White House had blocked FDA’s plans to formally publish the safety guidelines based on the two-month data requirement, arguing there was “no clinical or medical reason” for it.But on Tuesday, the FDA posted the guidance on its website, making clear that regulators plan to impose the safety standards for any vaccine seeking an expedited path to market.FDA Commissioner Stephen Hahn said in a statement that he hoped the guidelines would help “the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy.”The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval. But FDA has made clear only vaccines that are shown to be safe and effective will be authorized for coronavirus.Former FDA acting commissioner Dr. Stephen Ostroff said the requirements seem reasonable given the agency is in largely “uncharted territory” in terms of considering emergency use of a vaccine. The agency has only previously cleared one vaccine through the method — a decades-old shot that was authorized to prevent anthrax poisoning in 2005.“There really is no margin for error here,” Ostroff said. “Even when you’re talking about limited use of a vaccine there has to be some level of assurance that there isn’t a risk here that would far outweigh the benefit.”Dr. Peter Marks, the head of FDA’s vaccine division, said Tuesday that the two-month follow-up requirement was chosen to be “something reasonably aggressive, but not too conservative — right in the middle.” He spoke at a symposium organized by Johns Hopkins University.Initial doses of vaccines for emergency use would likely be reserved for medical workers and people with health conditions that make them particularly vulnerable to coronavirus. Full FDA approval for the general population will require significantly more data and is not expected until mid-2021.The White House attempt to block the guidance followed a string of instances in which the Trump administration has undercut its own medical experts working to combat the pandemic. FDA’s Hahn has been attempting to shore up public confidence in the vaccine review process for weeks, vowing that career scientists, not politicians, will decide if the shots are safe and effective.Pfizer CEO Albert Bourla has stoked excitement by saying that he expects data on whether the company’s candidate works to be ready in late October. But a number of variables would still have to align for the company to submit, and the FDA to review and greenlight, a vaccine application before Nov. 3. Pfizer’s competitors Moderna, AstraZeneca and Johnson & Johnson are working on longer research timelines.Vaccine development typically takes years, but the U.S. government has invested billions in efforts to accelerate the process and help multiple drugmakers prepare multiple candidates. All the doses will be purchased by the federal government for use vaccinating the U.S. population.Beyond exposing the rift between the White House and FDA, the delay in releasing the guidelines may have had limited practical effect.FDA scientists have been discussing the guidelines publicly for weeks and have made clear that the recommendations have already been shared with each of the vaccine developers.Former FDA Commissioner Scott Gottlieb said Tuesday that drugmakers depend on the FDA’s science-based endorsement to vouch for the safety and effectiveness of their products.“I can’t imagine a circumstance where a sponsor would challenge or seek to undermine the FDA’s role here,” Gottlieb said at the COVID-19 symposium. “This is precisely the moment when we need an objective, neutral arbiter.”Last week, Gottlieb and six other former FDA commissioners blasted the Trump administration for “undermining the credibility” of the agency in a op-ed calling for the release of the then-stalled vaccine guidelines.“Scientists should make decisions based on data, unfettered by political pressure or the intrusions of ideology or vested interests,” the officials wrote.___AP Medical Writer Lauran Neergaard contributed to this report.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5644

The Democratic National Committee chairman assured supporters Thursday that a scaled-down convention would go on as scheduled in August in Milwaukee, Wisconsin."From the very beginning of this pandemic, Democrats have put the health and safety of the American people first. Unlike Trump, we followed the science, listened to doctors and public health experts, and worked through plans to protect lives," DNC Chairman Tom Perez said in a series of tweets. "That's how we made the decision to hold a responsible convention that will bring our country together, ensure our delegates can take care of official business without risk to public health, and still shine a spotlight on our host community of Milwaukee."In June, DNC leaders announced plans to transform the convention amid the pandemic, moving it from the Fiserv Forum, a 17,000-seat arena, to Wisconsin Center, a convention center. The DNC also advised state delegates to not travel to Milwaukee.Presumptive Democratic nominee Joe Biden still plans to accept the nomination in Milwaukee. The DNC is slated to begin Aug. 17. 1089

The family of Pfc. Vanessa Guillen, an Army soldier who was allegedly killed by a fellow soldier and his girlfriend, met with President Donald Trump on Thursday.Guillen's family began the day with a morning march on the National Mall in support of a military-focus sexual harassment bill bearing her name. The family and their attorney later met with the President at the White House.The event was closed to the press."It hit me very hard," Trump said later Tuesday about meeting with Guillen's family, according to CBS News. "We didn't want this to be swept under the rug."Guillen was last seen on April 22 at Fort Hood, Texas, where she had been stationed. On June 30, Guillen's dismembered remains were found on the banks of a nearby river.Hours later, a suspect in the case, Spc. Aaron Robinson died by suicide during a standoff with police. Robinson's girlfriend, Cecily Ann Aguilar, was later charged with assisting in hiding Guillen's body. Aguilar has pleaded not guilty.Guillen's family maintains that she had been sexually harassed by Robinson and others prior to her disappearance. They claim she did not report the abuse to her superior officers because she feared retribution.While an investigation into sexual harassment against Guillen remains open, the Army has not yet confirmed the family's claims. According to ABC News, the Army has confirmed that Guillen may have been harassed, but it was not of a sexual nature.The bill for which Guillen's family was marching, the #IAmVanessaGuillen Bill, would allow military members to file harassment claims with third-party agencies instead of within their chain of command."We will not accept anything less than justice for Vanessa," Attorney Natalie Khawam said, according to KPRC-TV in Houston. "When someone volunteers to serve our country, they deserve to be treated with dignity and respect by their fellow service members. This bill will help us provide the protection and respect to others that was denied to Vanessa." 1995

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201